+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Spinocerebellar Ataxia (SCA)- Epidemiology Forecast to 2028

  • ID: 4833464
  • Report
  • September 2019
  • Region: Global
  • 80 pages
  • DelveInsight
1 of 2
‘Spinocerebellar Ataxia (SCA) - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Spinocerebellar Ataxia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2028

Spinocerebellar Ataxia (SCA) - Disease Understanding

Spinocerebellar Ataxia is a genetic disorder which is progressive, degenerative, and often fatal. The clinical marker of all SCAs is a progressive loss of balance and coordination accompanied by slurred speech. The mobility and communicative skills of individuals with an SCA are restricted, which strongly impairs quality of life, and many SCAs lead to premature death.

Spinocerebellar Ataxia Epidemiology

The Spinocerebellar Ataxia (SCA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Spinocerebellar Ataxia are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Spinocerebellar Ataxia Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Spinocerebellar Ataxia and type-specific prevalent cases) scenario of Spinocerebellar Ataxia (SCA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to the publisher, the total number of prevalent cases of Spinocerebellar Ataxia (SCA) in 7 MM was found to be 42,043, in the year 2017.

Report Scope
  • The report covers detailed overview of Spinocerebellar Ataxia explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Spinocerebellar Ataxia in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by prevalence of SCA, total diagnosed prevalence of Spinocerebellar Ataxia, incidence of Spinocerebellar Ataxia, and type-specific prevalent cases in 7MM
Key strengths
  • 10 Year Forecast of Spinocerebellar Ataxia epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of SCA
  • Prevalent Cases according to segmentation: Prevalence, Diagnosed Cases, Type specific
Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Disease Background and Overview
2.1. Introduction
2.2. Subtypes of SCA
2.2.1. SCA1
2.2.2. SCA2
2.2.3. SCA3
2.2.4. SCA6
2.2.5. SCA7
2.3. Causes and risk factors
2.4. History
2.5. Signs and Symptoms
2.6. Pathophysiology
2.7. Diagnosis
2.8. Biomarkers
2.8.1. Neuroimaging biomarkers
2.8.2. Oculomotor biomarkers
2.8.3. Biological biomarkers

3. Epidemiology and Patient Population
3.1. Key Findings
3.2. 7MM Total Patient Population of Spinocerebellar Ataxia

4. Country Wise-Epidemiology of Spinocerebellar Ataxia
4.1. United States
4.1.1. Assumptions and Rationale
4.1.2. Total Prevalent Population of Spinocerebellar Ataxia in the United States
4.1.3. Total Diagnosed Cases of Spinocerebellar Ataxia in the United States
4.1.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the United States
4.2. EU5 Countries
4.2.1. Assumptions and Rationale
4.3. Germany
4.3.1. Total Prevalent Population of Spinocerebellar Ataxia in Germany
4.3.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Germany
4.3.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the Germany
4.4. France
4.4.1. Total Prevalent Population of Spinocerebellar Ataxia in France
4.4.2. Total Diagnosed Cases of Spinocerebellar Ataxia in France
4.4.3. Type-Specific Prevalence of Spinocerebellar Ataxia in France
4.5. Italy
4.5.1. Total Prevalent Population of Spinocerebellar Ataxia in Italy
4.5.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Italy
4.5.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Italy
4.6. Spain
4.6.1. Total Prevalent Population of Spinocerebellar Ataxia in Spain
4.6.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Spain
4.6.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Spain
4.7. United Kingdom
4.7.1. Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom
4.7.2. Total Diagnosed Cases of Spinocerebellar Ataxia in the United Kingdom
4.7.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom
4.8. Japan
4.8.1. Assumptions and Rationale
4.8.2. Total Prevalent Population of Spinocerebellar Ataxia in Japan
4.8.3. Total Diagnosed Cases of Spinocerebellar Ataxia in Japan
4.8.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the Japan

5. Treatments
5.1. Potential treatments
5.2. U.S. Guidelines
5.2.1. Local Susceptibility of Host Tissue
5.3. Europe Guidelines
5.4. Management of Spinocerebellar Ataxia

6. Unmet Needs

7. Appendix
7.1. Report Methodology

8. Publisher Capabilities

9. Disclaimer

10. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll